Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies

Détails

ID Serval
serval:BIB_1DD48464868E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies
Périodique
Lasers in Surgery and Medicine
Auteur(s)
Ris  H. B., Altermatt  H. J., Nachbur  B., Stewart  C. M., Wang  Q., Lim  C. K., Bonnett  R., Althaus  U.
ISSN
0196-8092 (Print)
Statut éditorial
Publié
Date de publication
1996
Volume
18
Numéro
1
Pages
39-45
Notes
Clinical Trial
Clinical Trial, Phase I
Journal Article --- Old url value: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8850464
Résumé
BACKGROUND and OBJECTIVE: Since there is no satisfactory treatment modality for diffuse malignant mesothelioma of the chest, we assessed surgical tumor resection followed by intraoperative photodynamic therapy with mTHPC in a phase I study. STUDY DESIGN/MATERIALS and METHODS: Since 1990, eight patients have undergone intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin (mTHPC-PDT) following thoracotomy and surgical tumor resection. RESULTS: mTHPC-PDT-mediated tumor necrosis was characterized by tumor infarction due to tumor vessel necrosis and thrombosis, and its extent depended on drug-light conditions; 650 nm light delivered at 0.1 W/cm2 for 10 J/cm2 48 h after iv administration of 0.3 mg mTHPC/kg resulted in a 10-mm-deep complete tumor necrosis. Skin photosensitivity was related to the drug dose applied and occurred up to 17 days after iv administration of 0.3 mg mTHPC/kg, mTHPC-PDT of brachial plexus infiltrated by mesothelioma resulted in pain relief without deterioration of nerve function. CONCLUSION: Tumor resection and intraoperative mTHPC-PDT of the chest cavity is feasible under clinical conditions and offers local tumor control of sites involved. However, distant tumor spread was not prevented by this combined treatment modality and optimization of mTHPC-PDT is warranted for further intraoperative application.
Mots-clé
Antineoplastic Agents/*therapeutic use Brachial Plexus/drug effects/pathology Combined Modality Therapy Dose-Response Relationship, Drug Feasibility Studies Humans Infarction/pathology *Intraoperative Care Mesoporphyrins/*therapeutic use Mesothelioma/*drug therapy/pathology/*surgery Necrosis Neoplasm Invasiveness Peripheral Nervous System Neoplasms/drug therapy *Photochemotherapy Radiation-Sensitizing Agents/*therapeutic use Skin/drug effects/radiation effects Thoracic Neoplasms/*drug therapy/pathology/*surgery Thoracotomy Thrombosis/pathology
Pubmed
Web of science
Création de la notice
29/01/2008 12:59
Dernière modification de la notice
20/08/2019 12:54
Données d'usage